Tisa-Cel Yields Durable Responses in R/R Follicular Lymphoma Our panel of experts discuss 3-year findings from the phase II ELARA study Dec 26, 2023 video
Mammo Responsibility Ups Screening; Opioids for Cancer Pain? Ignored Signs of CRC News, features, and commentary about cancer-related issues Dec 21, 2023
JAK1 Inhibitor Shows 'Remarkable' Activity in T-Cell Lymphoma Phase II findings on golidocitinib will form the basis of an accelerated approval application Dec 15, 2023
Hematocrit Stabilized in Polycythemia Vera Treated With Novel Hepcidin Mimetic Rusfertide maintained hematocrit Dec 15, 2023
Ibrutinib-Venetoclax Improves PFS in R/R Mantle Cell Lymphoma Will results revive ibrutinib role in MCL following withdrawal of accelerated approval? Dec 13, 2023
'Half-Matched' BMTs Effective in Severe Sickle Cell Disease High survival rates observed in patients not normally suitable for transplant Dec 13, 2023
Pomalidomide Cuts Severe Epistaxis in Genetic Bleeding Disorder 24 weeks of daily treatment significantly reduced recurrent nosebleeds in HHT trial Dec 13, 2023
Four Drugs Top Three for Upfront Treatment of Multiple Myeloma Adding anti-CD38 antibodies boosts response and PFS, but timing, sequencing, cost questioned Dec 13, 2023
Menin Inhibitor Yields 63% ORR in Heavily Pretreated Acute Leukemia Investigational drug revumenib now under review at FDA for KMT2A-rearranged disease Dec 12, 2023
Ruxolitinib Combinations Reduce Spleen Volume in Myelofibrosis Combos with navitoclax or pelabresib led to more patients achieving reductions Dec 12, 2023
Axatilimab Shows Efficacy in Recurrent/Refractory GVHD Highest overall response rate and least toxicity seen with lowest dose Dec 11, 2023
MRD Tied to Allo-Transplant Benefit in NPM1-Mutated Acute Myeloid Leukemia No advantage for MRD-negative patients in first remission after induction, regardless of FLT3 ITD Dec 11, 2023
A Closer Look at the Approval of CRISPR/Cas9 Gene Therapy for Sickle Cell Disease This landmark event brings up broader considerations and implications for other diseases Dec 11, 2023
ASCT Tops CAR T-Cell Therapy for Relapsed LBCL in Complete Remission Better 2-year PFS, OS, but not applicable to primary refractory disease Dec 10, 2023
Lovo-Cel 'Life-Changing, Transformative' in Sickle Cell Disease Near complete resolution of pain events in patients, including adolescents Dec 10, 2023
AI and Breast Cancer Screening; Cancer After Treatment for Sickle Cell Also in TTHealthWatch: mail-in cervical cancer screening kits Dec 09, 2023 podcast
Milestone Gene Therapies for Sickle Cell Disease Greenlit by FDA Casgevy and Lyfgenia approved for one-time treatment of sickle cell disease Dec 08, 2023
FDA Approves Oral Factor B Inhibitor for Paroxysmal Nocturnal Hemoglobinuria Iptacopan tops C5 Inhibitors for sustained hemoglobin levels, eliminating need for transfusion Dec 06, 2023
Rituximab Maintenance Boosts Survival for Older Adults With MRD-Negative MCL Patients with treatment-sensitive disease may benefit most from continued treatment, says expert Dec 05, 2023
Novel Therapy Reduced Transfusion Dependence in Lower-Risk MDS 40% of patients treated with imetelstat were transfusion-free for at least 8 weeks Dec 04, 2023
Non-Covalent BTK Inhibitor Approved for CLL Response rates with pirtobrutinib reached 72% in heavily pretreated patient population Dec 04, 2023
FDA Investigating 'Serious Risk' of Malignancy After CAR-T Therapy Applies to all approved therapies, but benefits still outweigh risks, agency says Nov 28, 2023
Apixaban Prophylaxis Fails to Reduce Clots in Pediatric ALL However, it may benefit children at increased risk of thrombosis Nov 20, 2023
Alteplase Not Harmful in NOAC Users, Even in a More Bleeding-Prone Cohort No excess brain bleeds in an Asian population receiving lytic therapy for stroke Nov 20, 2023
Opioid Doc Sentenced; World's First Sickle Cell Gene Tx; FTC Warns Diet Influencers Health news and commentary from around the Web gathered by 51³ΙΘΛΆ―Βώ staff Nov 17, 2023
FDA Panel: Tolerating Approval Outliers Would Set 'Dangerous Precedent' No easy answers for two drugs for rare lymphoma on long cruise with accelerated approval Nov 16, 2023
FDA OKs Product to Thwart Bloodstream Infections During Dialysis Taurolidine-heparin solution reduced infections by 71% versus heparin alone Nov 15, 2023
Lymphoma Drug Copanlisib to Be Pulled From U.S. Market Failed confirmatory trial takes down another PI3K inhibitor Nov 14, 2023
First Treatment Approved for Genetic Clotting Disorder Adzynma indicated as prophylactic or on-demand enzyme replacement therapy in cTTP Nov 10, 2023
Vitamin D for Neuropathy; Good & Bad News for CAR-T; New Labeling for Surgical Mesh News, features, and commentary about cancer-related issues Nov 10, 2023
Wearables as Cancer Monitors; No China Price Break; Cancer Mystery in Appalachia News, features, and commentary about cancer-related issues Nov 03, 2023
Potential Cure for Sickle Cell Clears Hurdle for Approval FDA advisors suggest the benefits of gene therapy outweigh risks of off-target editing Oct 31, 2023
FDA Reviewers Question Safety of Sickle Cell Gene Therapy Efficacy results "strongly positive," but unintended off-target effects a question Oct 30, 2023
Soap to Fight Skin Cancer; $1,000 Early Cancer Detection Test; FDA Approval in MDS News, features, and commentary about cancer-related issues Oct 27, 2023
Quad Regimen for High-Risk Myeloma Produces High Rates of Durable MRD Negativity Two-thirds of transplant-eligible patients met endpoint with isatuximab/KRd Oct 19, 2023
Lonely Cancer Deaths; Virtual Reality for Pain; 3D Models May Improve Treatment News, features, and commentary about cancer-related issues Oct 19, 2023
Emicizumab Can Delay Immunosuppressive Tx in Acquired Hemophilia A "Strategy will probably be practice-changing," says expert Oct 18, 2023
Hemoglobin Targets a Good Idea for Massively Transfused Patients Outcomes improved with values approaching 10 g/dL Oct 16, 2023
